Anrs, Emerging Infectious Diseases

This study tests two experimental COVID-19 booster vaccines alongside two already-approved ones in 48 healthy adults aged 18 to 65. Participants receive one injection and are monitored for side effects and antibody levels over 48 weeks. The goal is to see if the new vaccines are …

This study compares a new intranasal (nose spray) COVID-19 booster vaccine, LVT-001, with the standard mRNA booster shot in 238 healthy adults. The goal is to see if the nasal vaccine is safe and triggers a strong immune response, especially in the nose and throat where the virus…

This study compares two HIV medications, doravirine and dolutegravir, in people who have never taken HIV treatment before. About 610 adults with HIV-1 will receive one of these drugs along with standard medicines. The goal is to see if doravirine works just as well as dolutegravi…

This trial tests whether giving the antiviral drug tenofovir disoproxil fumarate (TDF) to pregnant women with active hepatitis B can prevent the virus from spreading to their babies. The women take TDF from the 28th week of pregnancy until six weeks after giving birth, and all ne…

This Phase III trial in sub-Saharan Africa tests whether giving higher doses of rifampicin plus linezolid, along with aspirin, can reduce deaths from tuberculous meningitis (TBM) in both HIV-positive and HIV-negative people. About 768 adolescents and adults will receive either th…

This study looks at whether giving a longer course (10 days instead of 5) or adding another antiviral (remdesivir) to the standard Paxlovid treatment helps immunocompromised people clear COVID-19 faster. About 256 adults with mild or no symptoms will be randomly assigned to diffe…

This phase 2 trial tests whether adding adalimumab (an arthritis drug) to standard tuberculosis meningitis treatment can reduce deaths in HIV-positive adults. About 130 participants in Brazil, Mozambique, and Zambia will receive adalimumab injections every two weeks for 10 weeks …

This Phase 3 trial tests whether taking HIV prevention pills only around the time of sex can reduce the risk of HIV infection in men who have sex with men. Participants take either TAF/FTC or TDF/FTC, starting with a dose 2 to 24 hours before sex and another dose a day later. The…

This study will follow 2000 adults in France who are starting treatment for tuberculosis. Researchers will collect health data and samples like blood, urine, and breath over two years to see how well treatments work. The goal is to learn more about TB care and build a biobank for…

This study follows 450 HIV-positive adults in France who can naturally control the virus without taking antiretroviral drugs. Researchers want to understand how their immune systems keep the virus in check and why some eventually lose that control. The goal is to learn more about…

This study follows up with 100 men who took part in the ANRS IPERGAY HIV prevention trial to see how many have developed high-grade anal lesions or anal cancer a decade later. Researchers will use a special test to look for HPV mutations and viral DNA integration in the body. The…